Initial Study of Malaria Vaccine Pfs25-EPA/Alhydrogel(Registered Trademark)

* INCLUSION CRITERIA: All of the following criteria must be fulfilled for a volunteer to participate in this trial: * Age between 18 and 50 years. * Good general health as a result of review of medical history and/or clinical testing at the time of screening. * Available for the duration of the trial. * Willingness to participate in the study as evidenced by signing the informed consent document. * If female: subject is willing to use reliable contraception methods for the period of at least 1month (2 months for oral contraceptive pills) prior to first vaccination to 3 months after last vaccination. Reliable methods of birth control include: pharmacologic contraceptives including oral, parenteral, and transcutaneous delivery; condoms with spermicide; diaphragm with spermicide; surgical sterilization; vaginal ring; transdermal patch; intrauterine device; abstinence; and post-menopause. EXCLUSION CRITERIA: A volunteer will be excluded from participating in this trial if any one of the following criteria is fulfilled: * Pregnancy as determined by a positive urine or serum human choriogonadotropin (Beta-hCG) test at any point during the study (if female). * Currently is lactating and breast-feeding (if female). * Behavioral, cognitive, or psychiatric disease that in the opinion of the investigator affects the ability of the participant to understand and cooperate with the study protocol. * Neutropenia as defined by an absolute neutrophil count \< 1500/mm(3). * Alanine transaminase (ALT) level above the laboratory-defined upper limit of normal. * Evidence of clinically significant neurologic, cardiac, pulmonary, hepatic, endocrine, rheumatologic, autoimmune, hematological, or renal disease by history, physical examination, and/or laboratory studies including urinalysis. * Other condition that in the opinion of the investigator would jeopardize the safety or rights of a participant participating in the trial or would render the subject unable to comply with the protocol. * History of receiving any investigational product within the past 30 days. * Receipt of antimalarial prophylaxis during the past 12 months, or planned travel to a destination which would require malaria prophylaxis during the period of participation. * Prior malaria infection by history. * Participant has had medical, occupational, or family problems as a result of alcohol or illicit drug use during the past 12 months. * History of a severe allergic reaction or anaphylaxis. * Severe asthma. This will be defined as: * Asthma that is unstable or required emergent care, urgent care, hospitalization or intubation during the past 2 years, or that requires the use of oral or parenteral corticosteroids. * Clinically significant reactive airway disease that does not respond to bronchodilators. * Positive ELISA and confirmatory Western blot tests for HIV-1. * Positive ELISA and confirmatory tests for hepatitis C virus (HCV). * Positive hepatitis B surface antigen (HBsAg) by ELISA. * Pre-existing autoimmune or antibody-mediated diseases including but not limited to: systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, Sjogren's syndrome, or autoimmune thrombocytopenia. * Known immunodeficiency syndrome. * Use of chronic (greater than or equal to 14 days) oral or intravenous corticosteroids (excluding topical or nasal) at immunosuppressive doses (i.e. prednisone \> 10 mg/ day) or immunosuppressive drugs within 30 days of starting this study. * Receipt of a live vaccine within past 4 weeks or a killed vaccine within past 2 weeks prior to entry into the study. * History of a surgical splenectomy. * Receipt of blood products within the past 6 months. * Previous receipt of an investigational malaria vaccine. * Refusal to allow storage of samples for future research. * Any medical, psychiatric, social, or occupational condition or other responsibility that, in the judgment of the Principal Investigator (PI), would interfere with the evaluation of study objectives.